Form 8-K - Current report:
SEC Accession No. 0001411685-25-000046
Filing Date
2025-06-17
Accepted
2025-06-17 16:44:53
Documents
16
Period of Report
2025-06-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtgn-20250617.htm   iXBRL 8-K 34993
2 EX-5.1 vtgn-202506178xkex51.htm EX-5.1 23643
3 EX-99.1 vtgn-20250612xex991_final.htm EX-99.1 85875
7 image01.jpg GRAPHIC 4984
8 imagea.jpg GRAPHIC 42987
  Complete submission text file 0001411685-25-000046.txt   344789

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtgn-20250617.xsd EX-101.SCH 1785
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtgn-20250617_lab.xml EX-101.LAB 21629
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtgn-20250617_pre.xml EX-101.PRE 12510
18 EXTRACTED XBRL INSTANCE DOCUMENT vtgn-20250617_htm.xml XML 2729
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 251053940
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)